Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a leading global provider of specialty medical devices for critical care and surgical procedures. Headquartered in Wayne, Pennsylvania, Teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.
The company’s diverse product portfolio spans across several key segments: vascular access, interventional, anesthesia, surgical, interventional urology, original-equipment manufacturing, and others. These segments collectively cover a wide range of medical needs, from complex surgical interventions to everyday critical care requirements.
Teleflex’s vascular access segment, contributing 24% to 2023 sales, includes innovative solutions for secure and reliable bloodstream access. The interventional segment, accounting for 17%, focuses on cutting-edge devices for minimally invasive procedures. Anesthesia and surgical segments, with 13% and 14% of sales respectively, offer advanced tools and technologies to improve patient outcomes during surgeries.
The company’s interventional urology segment, noted for its UroLift™ System, addresses benign prostatic hyperplasia (BPH) with minimally invasive solutions that preserve patient quality of life. Original-equipment manufacturing and other segments contribute 11% and 10% of sales respectively, underscoring Teleflex’s broad manufacturing capabilities and diverse product offerings.
Teleflex's geographic exposure is primarily in the United States, which generates 60% of its revenue, with international markets contributing the remainder. The company’s global reach and diverse product lines highlight its significant impact on the healthcare industry worldwide.
In recent years, Teleflex has achieved notable success with a 6.5% constant currency revenue growth in 2023, driven by the expansion of its geographic presence and the launch of innovative new products. The company has strategically acquired Palette Life Sciences AB, enhancing its portfolio and operational efficiencies.
Teleflex remains committed to its mission of providing solutions that improve outcomes and enhance safety for patients and healthcare providers. By leveraging purpose-driven innovation, Teleflex continues to address unmet clinical needs and advance healthcare technologies.
For more information about Teleflex and its comprehensive product offerings, please visit teleflex.com.
Teleflex has received FDA clearance for expanded use of its specialty catheters and coronary guidewires in chronic total occlusion percutaneous coronary interventions (CTO PCI). CTOs, affecting nearly 20% of patients, are significant blockages that lead to ischemia. The CTO-PCI study demonstrated a 93.3% technical success rate and over 75% procedural success, emphasizing the effectiveness of Teleflex's devices in complex cases. This advancement reflects Teleflex's commitment to innovative medical technologies that enhance patient outcomes.
Teleflex (NYSE: TFX) will host a conference call on February 24, 2022, at 8:00 a.m. Eastern Time to discuss its fourth quarter and full year 2021 financial results. Investors can register for the call via the provided link or access it through an audio webcast on Teleflex's website. A replay will be available later that day. Teleflex specializes in medical technologies aimed at enhancing health and quality of life through innovative solutions across various medical fields, including vascular access and emergency medicine.
Teleflex is set to have its Chairman, President, and CEO, Liam Kelly, speak at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 4:30 p.m. ET. The event will be accessible via a live audio webcast on the Teleflex investor relations website, along with presentation slides. Known for its innovative medical technologies aimed at improving health outcomes, Teleflex operates in diverse fields including vascular access, interventional cardiology, and emergency medicine. Further details can be found on their website.
Teleflex Incorporated has received reimbursement approval for its UroLift System to treat benign prostatic hyperplasia (BPH) in Japan, effective April 1, 2022. This minimally invasive procedure offers symptom relief and improved quality of life for men suffering from BPH. CEO Liam Kelly emphasized the strategic investment in UroLift's commercial capabilities in Japan, aiming to train medical staff by early 2022. The UroLift System, already used in over 300,000 cases worldwide, is expected to significantly benefit the over two million affected men in Japan.
Teleflex Incorporated (NYSE: TFX) has announced a worldwide recall of its Arrow-Trerotola™ Over-The-Wire PTD® Kit due to a defect where the inner lumen can detach from the device’s basket. This recall affects products manufactured between October 2019 and July 2021, classified as a Class I recall by the FDA. The company received seven complaints, with no reported long-term complications. Consumers are advised to discontinue use and return all affected products. The recall notice, including product codes and lot numbers, is available on their website.
Teleflex (NYSE: TFX) has been named the top large company in the MedReps.com Best Places to Work in Medical Sales 2022 survey. This marks the fifth consecutive year Teleflex has earned this honor. The survey, which included over 2,300 medical sales professionals, highlighted key factors such as pay, leadership, and culture as significant for employees when choosing an employer. Teleflex's leadership expressed pride in the award, emphasizing the company's commitment to innovation and employee engagement.
Teleflex Incorporated (NYSE: TFX) is participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 22 to December 2, 2021. A pre-recorded presentation will be available on their investor website at 10 AM ET on November 22. Additionally, 1x1 meetings are scheduled for December 2, which can be requested through Piper Sandler. Teleflex focuses on innovative medical technologies across various fields including vascular access and emergency medicine, aiming to enhance patient health and quality of life.
Teleflex has partnered with Explorer Surgical to enhance training for urologists using the UroLift® System. This collaboration introduces the Explorer Live digital platform, promoting remote learning and collaboration through an interactive digital playbook. Surgeons can access tailored surgical information, real-time education, and video capabilities during procedures. The UroLift System offers a minimally invasive solution for benign prostatic hyperplasia, improving patient outcomes and access to effective treatments.
Teleflex (NYSE: TFX) responded to the November 3, 2021, release of the CMS 2022 Medicare Physician Fee Schedule (MPFS) Final Rule, effective January 1, 2022. The rule reduces Non-Facility Practice Expense Relative Value Units, impacting reimbursement for over 600 procedures, including the UroLift System. CEO Liam Kelly expressed disappointment, noting potential patient migration to outpatient settings due to reimbursement changes. The UroLift CPT codes will see fee reductions of 8% and 11%, respectively, and a phased implementation over four years. Financial implications will be discussed in Q4 2021 results.
Teleflex (NYSE: TFX) announced that its UroLift® System won a Bronze Award for 'Best New Branded Television Campaign' and an Honorable Mention for 'Best Branded Website' at the DTC National Advertising Awards. The successful 25-week campaign highlighted lower urinary tract symptoms related to benign prostatic hyperplasia (BPH) and resulted in a 146% increase in website traffic. This recognition showcases Teleflex's creativity in a competitive space dominated by larger pharmaceutical companies.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
What does Teleflex Incorporated do?
Where is Teleflex Incorporated headquartered?
How many people does Teleflex employ?
What are the main segments of Teleflex's business?
What percentage of Teleflex’s revenue comes from the United States?
What recent acquisitions has Teleflex made?
What is the UroLift™ System?
What was Teleflex's revenue growth in 2023?
How can one access Teleflex's investor conference calls?
What is the mission of Teleflex Incorporated?
